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Background. The mitogen-activated protein kinase (MAPK)
cascade is an important intracellular mediator of angiotensin
II (Ang II)-induced cell growth and differentiation. Here, we
examined the effect of angiotensin II type 1 receptor (AT1)
receptor blockade on renal injury and MAPK activity in Dahl
salt-sensitive (DS) rats.
Methods. DS rats were maintained on a high (H: 8.0%NaCl,
N = 8) or low (L: 0.3%NaCl, N = 7) salt diet, or H + can-
desartan cilexetil (10 to 15 mg/kg/day, N = 8). Urinary protein
excretion (UproteinV), renal cortical collagen content, and
glomerular injury (assessed by semiquantitative morphomet-
ric analysis) were determined after 4-week treatments. Plasma
and kidney Ang II levels were measured by radioimmunoassay.
Protein levels of AT1 and AT2 receptors in the renal cortical tis-
sues were analyzed by Western-blotting analyses. MAPKs activ-
ities, including extracellular signal-regulated kinases (ERK)1/2,
c-Jun NH2-terminal kinases (JNK), p38 MAPK, and Big-
MAPK-1 (BMK1), were measured by Western-blotting anal-
yses or in vitro kinase assays.
Results. DS/H rats showed higher mean blood pressure
(MBP), UproteinV, and renal cortical collagen content than DS/L
rats. Increased ERK1/2, JNK, and BMK1 activities were ob-
served in renal cortical tissues of DS/H rats (approximately 6.3-,
4.5-, and 2.5-fold, respectively), whereas p38 MAPK activity was
unchanged. Plasma Ang II levels were significantly reduced in
DS/H rats compared with DS/L rats, whereas kidney Ang II con-
tents and AT1 receptor protein levels were similar. Candesartan
did not alter MBP, but significantly reduced UproteinV and colla-
gen content, and ameliorated progressive sclerotic and prolifer-
ative glomerular changes. Furthermore, candesartan decreased
renal tissue Ang II contents (from 216 ± 19 to 46 ± 3 fmol/mL)
and ERK1/2, JNK, and BMK1 activities (−45%, −60%, and
−70%, respectively) in DS/H rats.
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Conclusion. In DS hypertensive rats, some of the renopro-
tective effects of AT1 receptor blockade are accompanied by
reductions in intrarenal Ang II contents and MAPK activity,
which might not be mediated through arterial pressure changes.
The Dahl salt-sensitive (DS) rat is a widely studied ge-
netic model of salt-sensitive hypertension that develops
renal damage characterized by glomerular injury [1–3].
Several studies have shown that plasma renin activity
(PRA) and circulating angiotensin II (Ang II) levels are
very low in these animals [4–6]. Furthermore, treatments
with angiotensin-converting enzyme (ACE) inhibitors or
Ang II receptor type 1 (AT1) receptor antagonists fail
to prevent the development of hypertension [2, 3, 5, 7],
suggesting that the systemic renin-angiotensin system is
not a predominant mediator of salt-induced hyperten-
sion. However, recent studies have shown that ACE
inhibitors or AT1 receptor antagonists ameliorated pro-
gressive sclerotic and proliferative glomerular changes
[2, 3, 7], and increased the life expectancy of such animals
[7, 8]. The data suggest that although the circulating renin-
angiotensin system is suppressed, the intrarenal renin-
angiotensin system plays a crucial role in the pathogenesis
of glomerular injury in DS hypertensive rats. However,
the precise mechanisms responsible for the renoprotec-
tive effects of AT1 receptor blockade remain unclear.
Glomerular diseases are commonly characterized by
mesangial cell overgrowth and excessive accumulation
of extracellular matrix proteins [9, 10, 11]. Ang II stim-
ulates cellular hypertrophy and proliferation in mesan-
gial cells through activation of multiple intracellular
signaling pathways, including mitogen-activated protein
kinases (MAPKs) [9, 11]. In cultured rat mesangial
cells, Ang II activates extracellular signal-regulated ki-
nases (ERK) 1/2 [12] and c-Jun NH2-terminal kinases
(JNK) [13], which belong to MAPK subgroups. Another
MAPK family member, p38 MAPK, was also activated
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by Ang II in these cells with high glucose [14]. Studies by
Hamaguchi et al [15] provided in vivo evidence that Ang
II infusion led to activation of glomerular ERK1/2 and
JNK, followed by an increase in arterial pressure. It has
also been shown in renal cortical slices that Ang II-
induced stimulation of the collagen I a2 chain gene is
blocked by a specific ERK/MAPK inhibitor or an AT1
receptor antagonist [16]. Collectively, these observations
indicate that the MAPK cascade is an important mediator
of Ang II-induced molecular actions in the kidney. Re-
cently, Hamaguchi et al [17] showed that enhancement
of glomerular ERK1/2 and JNK activities is associated
with an increase in urinary protein excretion (UproteinV)
in DS hypertensive rats. Although these data suggest that
MAPK activation is involved in the progression of renal
injury in these animals, the effects of AT1 receptor block-
ade on renal MAPK activity has not been determined.
The present study was designed to characterize the
intrarenal renin-angiotensin system and MAPKs activi-
ties, and examine the effects of AT1 receptor blockade
on renal injury as well as kidney tissue Ang II levels
and MAPKs activities in DS hypertensive rats. We mea-
sured the activities of the classic MAPKs (ERK1/2, JNK,
and p38 MAPK) and a new MAPK family member, Big
MAPK-1 (BMK1) [18–20]. We obtained evidence that
the intrarenal renin-angiotensin system is not suppressed
in DS hypertensive rats, and that the renoprotective ef-
fects of AT1 receptor blockade are associated with re-
ductions in kidney Ang II contents, and the activities of
ERK1/2, JNK, and BMK1.
METHODS
Animal preparation
All experimental procedures were performed accord-
ing to the guidelines for the care and use of animals es-
tablished by the Kagawa Medical University. Male 6- or
7-week-old DS and Dahl salt-resistant (DR) rats (Seac
Yoshitomi, Fukuoka, Japan) weighing 200 to 225 g at the
beginning of the experiments were selected at random
to receive high salt (H: 8% NaCl, Oriental Yeast, Tokyo,
Japan) or low salt (L: 0.3% NaCl, Oriental Yeast) rat
chow for 4 weeks. The numbers of animals used were as
follows: 8, 7, 7, 7 for DS/H, DS/L, DR/H, and DR/L rats,
respectively. In a separate experimental series, DS (N =
8) and DR rats (N = 7) were fed a high salt diet (8%
NaCl) and treated with candesartan cilexetil (Takeda
Pharmaceutical Industries, Ltd., Osaka, Japan) at a dose
of 11 ± 1 mg/kg body weight per day. The dose of can-
desartan cilexetil was chosen on the basis of results from
previous rat studies [21]. Candesartan cilexetil was dis-
solved in drinking water containing ethanol (0.05% to
0.075% v/v), polyethylene glycol 300 (0.05% to 0.075%
v/v), and sodium bicarbonate (0.75 to 1.13 mmol/L), as de-
scribed previously [22, 23]. In preliminary experiments,
the effects of the vehicle on mean blood pressure (MBP),
UproteinV, renal cortical collagen content, plasma and kid-
ney Ang II levels, and renal cortical tissues MAPK activ-
ities were examined in other DR/H and DS/H rats (N =
5 each). The results showed that no parameters were al-
tered by treatment with vehicle in both DR/H and DS/H
rats (data not shown).
MBP was measured every week in conscious rats by
tail-cuff plethysmography (BP-98A; Softron Co., Tokyo,
Japan). Twenty-four–hour urine samples were collected
one day before harvesting. Blood and kidney samples
were harvested at the end of the fourth week. After de-
capitation, trunk blood was collected into chilled tubes
containing an inhibitor mixture (5 mmol/L EDTA +
20 lmol/L enalaprilat + 1.25 mmol/L O-phenanthroline
+ 10 lmol/L pepstatin) and processed for measurements
of plasma Ang II [24, 25]. Blood was also collected into
chilled tubes containing 5 mmol/L EDTA for measuring
plasma renin activity (PRA) [25]. Just after removal of
the kidneys, half of one kidney was homogenized in cold
methanol and processed for measurements of kidney Ang
II contents [24–26]. The other half of this kidney was fixed
in 10% buffered paraformaldehyde for histologic exam-
ination. The remaining kidney was snap-frozen in liquid
nitrogen and stored at −80◦C until processing for protein
extraction and analysis of collagen content.
Analysis of kidney samples for AT1 receptors
and MAPKs
Protein levels of AT1 and AT2 receptors in the renal
cortical tissues were analyzed by Western blotting using
antibodies against AT1 and AT2 receptors (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA), as previously
described in detail [26, 27]. To check for equal loading,
membranes were reprobed with an antibody against b-
actin (Sigma Chemical Co., St. Louis, MO, USA). All
values were normalized by arbitrarily setting the densit-
ometry of DS/L rats to 1.0. Previously, we found that
activation of ERK1/2 or p38 MAPK by an in-gel ki-
nase assay with specific substrates and immunoblotting
for phospho-ERK1/2 or phospho-p38 MAPK were highly
correlated (R2 = 0.90) [18, 28, 29]. Therefore, we used im-
munoblotting with antibodies against phospho-ERK1/2
and phospho-p38 MAPK (Cell Signaling Technology Inc.,
Beverly, MA, USA) to evaluate ERK1/2 and p38 MAPK
activation, as described previously [28, 29]. JNK activity
was measured using a commercially available kit based on
the phosphorylation of recombinant c-Jun. Immunoblot-
ting was performed with antibodies against phospho-c-
Jun (Cell Signaling Technology, Inc.) [28, 29]. BMK1
activity was measured by Western blotting analysis with
a phospho-specific antibody for ERK5 (Cell Signaling
Technology Inc.), as previously described [18, 19]. We also
evaluated total ERK1/2, JNK, p38 MAPK, and BMK1
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protein expression using pan-ERK1/2, JNK, p38 MAPK,
and BMK1 (ERK5) antibodies (Cell Signaling Technol-
ogy Inc.). All values were normalized by arbitrarily set-
ting the densitometry of DS/L rats to 1.0.
Histologic examination
Kidneys were fixed with 10% formalin (pH 7.4), em-
bedded in paraffin, sectioned into 4-lm slices, and stained
with Azan or hematoxylin-eosin (HE) reagents. The
severity of glomerular injury score was evaluated using
light microscopy according to previously described meth-
ods [2, 7, 30]. A minimum of 50 glomeruli was examined
in each specimen. Scoring of mesangial matrix expansion
was evaluated using the specimens with Azan staining as
follows: 0 = no matrix expansion; 1 = minor; 2 = weak;
3 = moderate; and 4 = strong. Proliferative lesions were
scored into 5 grades using specimens with HE staining
as follows: 0 = no proliferation; 1 = minor (segmental
lesion <25%); 2 = mild (25%<segmental lesion<50%);
3 = moderate (diffuse proliferation without severe scle-
rotic change); and 4 = severe (diffuse proliferation with
nearly complete sclerosis).
Analytical procedures
UproteinV was determined using a protein assay kit
(MicroTP-test, Wako, Japan). PRA and Ang II levels
were measured as previously reported [24–26]. Urinary
excretions of sodium (UNaV) and potassium (UKV) were
measured using flame photometry (Hitachi 750; Tokyo,
Japan) [31]. Renal cortical tissue collagen content was
determined on the basis of the hydroxyproline concen-
tration, as previously described [32].
Statistical analysis
The values are presented as mean ± SE. Statistical
comparisons of the differences were performed using
one-way or two-way analysis of variance combined with
Newman-Keuls post-hoc test. P < 0.05 was considered
statistically significant.
RESULTS
Blood pressure, kidney weight, UproteinV, UNaV, UKV,
and renal cortical collagen accumulation
MBP was identical among the 5 groups at the beginning
of the protocol. As shown in Figure 1A, DS/H rats pro-
gressively developed hypertension (MBP; 179 ± 5 mm
Hg at 4 weeks). After 4 weeks of a high-salt diet, kidney
weights and kidney weight-to-body weight ratios of DS/H
rats were significantly higher than those of DR/L, DR/H,
and DS/L rats (Table 1). UproteinV was significantly in-
creased in DS/H rats compared with DS/L, DR/H, and
DR/L rats (Fig. 1B). Candesartan did not alter MBP, kid-
80
100
120
140
160
180
200
M
BP
,
 
m
m
 H
g
0 1 2 3 4
Age, weeks
DR/L rats
DS/L rats
DR/H rats
DS/H rats
DR/H rats + C
DS/H rats + C
A
0
100
200
300
400
U p
ro
te
in
V,
 
m
g/
da
y
Low High High + C Low High High + C
DR rats DS rats
P < 0.01
B
Fig. 1. (A) Mean blood pressure (MBP) profile in Dahl rats at 0, 1, 2, 3,
and 4 weeks. ∗P < 0.05 vs. baseline. †P < 0.05 vs. DS/L rats. (B) Urinary
protein excretion in Dahl rats at 4 weeks. MBP and urinary protein
excretions in DS/H rats were significantly higher than those in DS/L,
DR/H, and DR/L rats. Candesartan treatment did not alter MBP but
significantly decreased urinary protein excretion in DS/H rats. ∗P < 0.05
vs. DS/L rats. DR/L rats: Dahl salt-resistant rats fed a 0.3% NaCl diet;
DR/H rats: Dahl salt-resistant rats fed an 8% NaCl diet; DS/L rats: Dahl
salt-sensitive rats fed 0.3% NaCl diet; DS/H rats: Dahl salt-sensitive rats
fed an 8% NaCl diet; C: candesartan.
ney weight, or UproteinV in DR/H rats (Fig. 1 and Table 1).
Furthermore, candesartan + DS/H rats did not exhibit
significantly reduced MBP compared with untreated
DS/H rats (168 ± 7 mm Hg at 4 weeks, Fig. 1A). However,
candesartan treatment significantly reduced increases in
kidney weights and UproteinV in DS/H rats, as shown in
Table 1 and Figure 1B, respectively. The high-salt diet
markedly increased UNaV and UKV in both DR and DS
rats. Treatment with candesartan also tended to increase
UNaV and UKV in both DR/H and DS/H rats, but these
changes were not statistically significant (Table 1).
Increased collagen accumulation, characterized by
Azan staining, was observed in DS/H rats (Fig. 2A). Af-
ter 4 weeks of treatment with a high-salt diet, the hydrox-
yproline concentration in the renal cortical tissue of DS/H
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Table 1. Effects of 4 weeks of a high-salt diet and candesartan (C) on body weight (BW), kidney weight (KW), urinary excretions of sodium
(UNaV) and potassium (UKV), and kidney collagen content in Dahl salt-resistant (DR) rats and Dahl salt-sensitive (DS)
DR rats DS rats
Low salt High salt High salt + C Low salt High salt High salt + C
(N = 7) (N = 7) (N = 7) (N = 7) (N = 9) (N = 9)
BW g 321 ± 2 319 ± 4 313 ± 4 342 ± 3 334 ± 2 346 ± 2
KW g 1.16 ± 0.04 1.21 ± 0.01 1.11 ± 0.03 1.31 ± 0.03 1.91 ± 0.06a 1.69 ± 0.03a,b
KW/BW % 0.36 ± 0.01 0.38 ± 0.01 0.34 ± 0.01 0.38 ± 0.01 0.56 ± 0.02a 0.49 ± 0.01a,b
UNaV mEq/day 1.1 ± 0.3 16.7 ± 1.4a 20.6 ± 1.8a 0.8 ± 0.1 19.2 ± 1.8a 23.7 ± 1.4a
UKV mEq/day 1.1 ± 0.1 3.8 ± 0.1a 4.1 ± 0.2a 1.1 ± 0.1 4.0 ± 0.2a 4.6 ± 0.1a
Kidney collagen content 12 ± 2 13 ± 1 10 ± 1 12 ± 3 24 ± 1a 16 ± 1a,b
lg/mg dry weight
Values are mean ± SE.
aP < 0.05 vs. the same strain on a low salt diet.
bP < 0.05, DS/a high salt diet vs. DS/a high salt diet + candesartan.
rats was 25 ± 1 nmol/mg. The calculated cortical collagen
content in DS/H rats was 24 ± 1 lg/mg, which was sig-
nificantly higher than those of DS/L, DR/H, DR/H +
candesartan, and DR/L rats (Table 1). In DS/H rats, can-
desartan treatment significantly decreased Azan staining
in glomeruli (Fig. 2A), as well as collagen content in the
renal cortex (Table 1).
Histologic findings
The glomerular histologic findings with Azan and HE
staining are illustrated in Figure 2. DR/L, DR/H, DR/H
+ candesartan, and DS/L rats showed normal glomeruli,
whereas DS/H rats exhibited severely damaged glomeruli
characterized by mesangial matrix expansion (Fig. 2A
and C) and cell proliferation (Fig. 2B and D). As shown in
Figure 2A-D, concurrent administration of candesartan
markedly ameliorated these glomerular changes in DS/H
rats.
PRA and Ang II levels in plasma and kidney
In DR rats, a high-salt diet significantly decreased PRA
(DR/H, 0.7 ± 0.2 ng Ang I/mL/hr; DR/L, 4.7 ± 0.8 ng Ang
I/mL/hr). DS/H rats also showed lower PRA compared
with DS/L rats (DS/H, 0.6 ± 0.2 ng Ang I/mL/hr; DS/L,
3.7 ± 0.5 ng Ang I/mL/hr). Plasma Ang II levels were
also reduced by a high-salt diet in both DR and DS rats
(Fig. 3A and B). In addition, DR/H rats showed signifi-
cantly lower kidney Ang II contents compared with those
of DR rats fed a low-salt diet (194 ± 9 vs. 357 ± 54
fmol/g, Fig. 3C). However, a high-salt diet did not re-
duce the kidney Ang II contents in DS rats (DS/H rats:
214 ± 34 fmol/g, DS/L rats: 216 ± 18 fmol/g, Fig. 3D). In
DR/H rats, candesartan treatment significantly increased
PRA (8.1 ± 2.3 ng Ang I/mL/hr) and plasma Ang II con-
centrations (102 ± 8 fmol/g, Fig. 3A), but did not alter
kidney Ang II contents (144 ± 16 fmol/g, Fig. 3C). Simi-
larly, candesartan treatment significantly increased PRA
(6.8 ± 2.2 ng Ang I/mL/hr) and plasma Ang II concen-
trations (68 ± 4 fmol/mL, Fig. 3B) in DS/H rats. How-
ever, kidney Ang II contents were markedly reduced by
treatment with candesartan in DS/H rats (46 ± 3 fmol/g,
Fig. 3D).
Renal cortical AT1 and AT2 receptors levels
Analyses of integrated densitometric values (IDV)
showed that the ratios for AT1 receptors were signifi-
cantly lower in the kidney samples of DR/H rats than
those of DR/L rats. In DS rats, however, cortical tissue
AT1 receptor levels were not suppressed by a high-salt
diet (Fig. 4A). On the other hand, analyses of IDV showed
that the ratios for AT2 receptors of kidney samples in
DS rats were significantly increased (1.9 ± 0.1-fold) by
a high-salt diet, whereas the levels in DR rats remained
unaltered (Fig. 4B). As a control study to check for equal
loading, membranes were reprobed with an antibody
against b-actin. The results showed that IDV levels were
unaltered among the groups.
Renal cortical MAPKs activities
ERK1/2 activities in renal cortical tissues of DS/H rats
were approximately 8-, 7-, and 6-fold higher than those
of DR/L, DR/H, and DS/L rats, respectively (Fig. 5A).
Furthermore, DS/H rats showed approximately 4-, 5-,
and 4-fold higher renal cortical JNK activities compared
with DR/L, DR/H, and DS/L rats, respectively (Fig. 5B).
In DR/H rats, candesartan treatment altered neither
ERK1/2 nor JNK activities (data not shown). However,
candesartan treatment significantly reduced ERK1/2 and
JNK activities by −45% and −60%, respectively, in DS/H
rats (Fig. 5A and B). On the other hand, renal cortical p38
MAPK activities were not significantly different among
all animals (Fig. 5C). BMK1 activities in renal cortical
tissues of DS/H rats were approximately 2.5-fold higher
than those of DR/L, DR/H, and DS/L rats (Fig. 5D).
Candesartan did not alter BMK1 activities in DR/H rats,
whereas increased BMK1 activities in DS/H rats were
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Fig. 2. Photomicrographs of glomeruli in Dahl rats. (A), Azan stain, and (B), HE stain, original magnification ×400, respectively. Glomerular scores
of (C) glomerular matrix expansion and (D) proliferation. A minimum of 50 glomeruli was examined in each specimen. DS/H rats exhibited severely
damaged glomeruli characterized by mesangial matrix expansion and cell proliferation. Candesartan markedly ameliorated these glomerular changes
in DS/H rats. ∗P < 0.05 vs. DS/L rats. DR/L rats: Dahl salt-resistant rats fed a 0.3% NaCl diet; DR/H rats: Dahl salt-resistant rats fed an 8% NaCl
diet; DS/L rats: Dahl salt-sensitive rats fed a 0.3% NaCl diet; DS/H rats: Dahl salt-sensitive rats fed an 8% NaCl diet. HE, hematoxylin-eosin; C,
candesartan.
normalized by candesartan treatment, as shown in Figure
5D. No differences in the amounts of ERK1/2, JNK, p38
MAPK, or BMK1 were observed in samples by Western
blotting analyses using pan-ERK1/2, JNK, p38 MAPK,
and BMK1 (ERK 5) antibodies (data not shown).
DISCUSSION
Otsuka et al [3] demonstrated increased glomerular
activator protein-1 transcription activities in DS hyper-
tensive rats. The authors also showed that AT1 receptor
blockade ameliorated glomerular injury and markedly
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Fig. 3. Plasma angiotensin II concentrations (A and B) and kidney an-
giotensin II contents (C and D) in Dahl rats. Plasma angiotensin II levels
were reduced by a high salt diet in both DR and DS rats. DR/H rats
showed significantly lower kidney angiotensin II contents compared
with those of DR rats fed a low salt diet. However, a high salt diet did
not reduce the kidney angiotensin II contents in DS rats. Candesar-
tan treatment increased the plasma angiotensin II concentrations, but
markedly decreased kidney angiotensin II contents in DS/H rats. ∗P <
0.05 vs. the same strain on a low salt diet. †P < 0.05: DR/H rats vs. DR/H
+ candesartan rats, or DS/H rats vs. DS/H + candesartan rats. DR rats,
Dahl salt-resistant rats; DS rats, Dahl salt-sensitive rats; C, candesartan.
reduced activator protein-1 activation in these animals
[2, 3]. These data indicate that locally produced Ang II
in the kidney contributes to the stimulation of transcrip-
tion and acts as a pivotal mediator of the pathogenesis of
glomerular changes in DS hypertensive rats. The present
study demonstrated that in DS rats, kidney Ang II con-
tents and renal cortical AT1 receptor protein levels were
not reduced by a high-salt diet. The results also demon-
strated that the renal cortical activities of ERK1/2 and
JNK, as well as a new MAPK family member, BMK1
[18–20], were significantly increased in DS hypertensive
rats. Similar to the results of previous studies [2, 3, 5, 7], it
was observed that AT1 receptor blockade with candesar-
tan did not significantly alter MBP in DS hypertensive
rats. However, candesartan markedly decreased kidney
Ang II contents and MAPK activities, and ameliorated
renal injury in these animals. These data suggest that in
DS hypertensive rats, some of the renoprotective effects
of AT1 receptor blockade are accompanied by reductions
in intrarenal Ang II contents and MAPK activities.
Accumulating evidence supports the notion that Ang
II is formed locally in the kidney [24–26, 33], and acts as a
pivotal mediator of the pathogenesis of renal injury dur-
ing the development of hypertension [9]. In agreement
with previous studies [4–6], the present study showed
that PRA and circulating Ang II levels were markedly
reduced by a high-salt diet in both DR and DS rats. It
was also observed that a high-salt diet significantly re-
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Fig. 4. Renal cortical (A) angiotensin II type 1 receptor AT1 and (B)
AT2 receptor protein levels in Dahl rats. All values were normalized
by arbitrarily setting the densitometry of DS/L rats to 1.0. DR rats
fed a high salt diet showed significantly reduced cortical tissue AT1
receptor protein levels compared with DR/L rats. However, cortical
tissue AT1 receptor levels in DS rats were unaffected by a high salt diet.
On the other hand, cortical tissue AT2 receptor levels were significantly
increased in DS/H rats. As a control study to check for equal loading,
membranes were reprobed with an antibody against b-actin. The results
showed that the densitometric values were unaltered among the groups
(data not shown). ∗P < 0.05 vs. the same strain on a low salt diet. DR
rats, Dahl salt-resistant rats; DS rats, Dahl salt-sensitive rats.
duced kidney Ang II contents in DR rats; however, a
high-salt diet did not reduce these levels in DS rats.
These results indicate that in DS hypertensive rats, the
intrarenal renin-angiotensin system is regulated in a
manner distinct from the circulating renin-angiotensin
system. It is possible that the failure to reduce kidney
Ang II contents allows for the continued contribution of
the intrarenal renin-angiotensin system to the progres-
sion of renal injury in DS hypertensive rats. However,
the precise mechanisms responsible for maintenance of
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Fig. 5. Renal cortical mitogen-activated pro-
tein kinases (MAPKs) activities in Dahl salt-
sensitive (DS) rats. Renal cortical tissues were
harvested, lysed, and used for subsequent
analyses. The activities of (A) extracellular
signal-regulated kinases (ERK) 1/2, (B) c-
Jun NH2-terminal kinases (JNK), (C) p38
MAPK, and (D) Big MAPK-1 (BMK1) were
measured as described in Methods. All val-
ues were normalized by arbitrarily setting
the densitometry of DS/L rats to 1.0. Den-
sitometric analysis of the immunoreactive
bands showed that a high salt diet markedly
increased renal cortical ERK1/2, JNK, and
BMK1 activities in DS rats, whereas p38
MAPK activity was unchanged. Candesartan
(C) treatment significantly reduced ERK1/2,
JNK, and BMK1 activities by −45%, −60%,
and −70%, respectively, in DS rats. On the
other hand, no differences in the amounts of
ERK1/2, JNK, p38 MAPK, and BMK1 were
observed in samples by Western blotting anal-
yses using pan-ERK1/2, JNK, p38 MAPK, and
BMK1 (ERK5) antibodies (data not shown).
the kidney Ang II contents are not clear from the present
study. Previous studies have shown reductions in total
renin activity, renin release, and renin mRNA in the renal
tissues of DS hypertensive rats [6]. Interestingly, we re-
cently found that DS hypertensive rats showed markedly
increased kidney angiotensinogen protein levels as well
as urinary excretion of angiotensinogen [34]. Thus, these
data suggest that in the kidneys of DS hypertensive rats,
increases in angiotensinogen production could help main-
tain Ang II levels in the presence of renin suppression.
Kobori et al [35] demonstrated that chronic infusion
of Ang II resulted in paradoxic increases in renal ex-
pression of angiotensinogen in rats. Other preliminary
studies have also shown that increases in intrarenal
angiotensinogen levels in Ang II-infused rats were pre-
vented by treatment with an AT1 receptor antagonist,
olmesartan (unpublished data, Kobori and Navar, 2003).
We also investigated intrarenal angiotensinogen levels
in Ang II-independent hypertension; our results showed
that intrarenal Ang II levels were significantly reduced
and intrarenal angiotensinogen levels were not increased
in deoxycorticosterone-salt hypertensive rats [36]. Thus,
these data indicate that AT1 receptor–mediated positive
feedback on angiotensinogen production is present in
the kidneys of Ang II-dependent hypertensive animals.
The present results show that candesartan does not alter
kidney Ang II contents in DR/H rats, but markedly re-
duces these levels in DS/H rats, suggesting a difference in
AT1 receptor-mediated intrarenal Ang II regulation be-
tween DR/H and DS/H rats. Precise mechanisms respon-
sible for candesartan-induced reductions in kidney Ang
II contents in DS/H rats remain unclear. However, it can
be speculated that augmented intrarenal angiotensino-
gen production is prevented by AT1 receptor blockade
with candesartan in DS/H rats, leading to reductions in
Ang II contents in the kidney.
AT1 receptor protein levels in renal cortical tissues
were reduced by a high-salt diet in DR rats; however,
these levels were not suppressed in DS rats. These data
are consistent with those observed by Nakaya et al
[22], who showed that mRNA expression of AT1A and
AT1B receptor was similar between DS/L and DS/H rats.
Previous studies have shown opposing changes in
glomerular/vascular and tubular AT1 receptor mRNA in
the kidneys in response to changes in sodium diet [37,
38]. Therefore, future studies will be required to clar-
ify regional and segment-specific regulation of intrarenal
AT1 receptor expression during the development of salt-
induced hypertension. We also found that AT2 receptor
protein levels were significantly increased in the renal cor-
tical tissues of DS hypertensive rats. In vitro studies have
shown that AT2 receptors suppress cell growth and in-
duce apoptosis [39]. Although the functional roles of AT2
receptors in the kidneys remain to be elucidated [33],
it can be speculated that the regulation of AT2 re-
ceptor expression in the kidneys might represent an
adaptive mechanism to attenuate renal injury in DS hy-
pertensive rats. Tea et al [40] showed that AT1 receptor
blockade with valsartan induced apoptosis and reduced
smooth muscle cell number in the aorta of spontaneously
hypertensive rats (SHR), and that the effects of valsar-
tan were prevented by a specific AT2 receptor antagonist,
PD123319. These data suggest that AT2 receptor–
mediated smooth muscle cell apoptosis contributes to the
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inhibitory effects of AT1 receptor antagonist on vascu-
lar hypertropic remodeling in cardiovascular disorders.
Morrissey et al [41] examined the effects of PD123319 on
renal fibrosis induced by ureteral obstruction in rats, and
found that PD123319 exacerbated fibrosis of the tubu-
lointerstitium in obstructive nephropathy; suggesting a
potential antifibrotic effect of AT2 receptors in the kid-
ney. Collectively, it is possible to speculate that at least
some of the renoprotective effects of candesartan in DS
rats are mediated through AT2 receptors. Effects of AT1
receptor blockade on angiotensin receptor levels in the
kidney have been less consistent [42–44]. For example,
treatment with the AT1 receptor antagonist 158,809 de-
creased both AT1 and AT2 receptor binding in kidneys
of autoimmune nephritis rats [42]. In kidneys of stroke-
prone SHR, candesartan did not alter mRNA expression
of AT1A and AT1B receptors, but significantly decreased
that of AT2 receptor [43]. Bonnet et al [44] performed
studies in diabetic SHR and found that AT1 receptor
blockade with irbesartan significantly increased mRNA
expression, binding, and immunostaining of AT1 receptor
in the kidney, whereas those of AT2 receptor were not al-
tered by irbesartan. It remains to be determined if these
discrepant observations relate to differences in strains,
methods used to assess angiotensin receptor expression,
or blood pressure changes. Clearly, further studies are
needed to determine the effects of candesartan on kid-
ney AT1 and AT2 receptor expression in DS rats.
In agreement with previous studies [2, 3, 5, 7], the
present results showed that candesartan did not decrease
blood pressure in DS/H rats, even at a high dose. Nakaya
et al [22] reported that prepubertal treatment (3 to 10
weeks) with candesartan caused partial attenuation of
hypertension in DS/H rats, and suggested that early treat-
ment with an AT1 receptor antagonist has multiple ben-
efits, including the suppression of a vascular amplifier
mechanism and central nervous function. Thus, it is pos-
sible that the age of the rats is critical for the antihy-
pertensive effects of candesartan. In the present study, a
high-salt diet markedly increased UNaV and UKV in both
DR and DS rats. It was also observed that treatment with
candesartan tended to increase UNaV and UKV in both
DR/H and DS/H rats, but these changes were not statis-
tically significant. For now, we cannot satisfactorily ex-
plain why candesartan did not increase UNaV and UKV
in these animals. However, several studies have shown
that UNaV and UKV are not altered by long-term ad-
ministration of AT1 receptor antagonists or angiotensin-
converting enzyme inhibitors in hypertensive high
salt-treated animals, including SHR fed a high-salt diet
[45] and deoxycorticosterone-salt hypertensive rats [46]
and mice [47].
MAPKs are important mediators of the intracellular
signal transduction pathways that are responsible for cell
growth and differentiation [9, 27–29]. Studies have shown
that ERK1/2 and JNK are activated by Ang II in cul-
tured mesangial cells [10, 12, 13] and isolated glomeruli
[15]. Thrarux et al [16] demonstrated that Ang II-induced
stimulation of the collagen I a2 chain gene was blocked
by a specific ERK inhibitor or AT1 receptor antagonist
in the kidney. These data suggest that Ang II stimu-
lates intrarenal collagen accumulation via AT1 receptor–
mediated MAPKs activation. Consistent with previous
studies [17], the present results showed that ERK1/2 and
JNK were markedly activated in the renal cortical tissues
of DS hypertensive rats. We also found that renal p38
MAPK activities were unchanged in these animals, sug-
gesting different activation of each MAPK subfamily. In
addition, the present study demonstrated that the activity
of a new MAPK family member, BMK1, was also signifi-
cantly increased in renal tissues of DS hypertensive rats.
To our knowledge, this is the first study to show BMK1
activity in renal tissue. Recent studies have indicated that
BMK1 is required for growth factor–induced cell prolif-
eration in various cells [18, 20]. More recently, Takeishi
et al [19] showed that BMK1 activity in heart tissue was
increased during the development of cardiac hypertro-
phy. Although specific roles of the BMK1 signaling path-
way in renal cells remain unclear, it can be speculated
that BMK1 plays a role as a novel signal transduction
pathway leading to renal injury in DS hypertensive rats.
In the present study, AT1 receptor blockade resulted in
amelioration of glomerular injury along with marked re-
ductions in renal MAPKs activities in DS hypertensive
rats, suggesting that renal injury is accompanied by AT1
receptor–mediated MAPKs activation, at least in part.
Since AT1 receptor blockade with candesartan did not
alter MBP in DS/H rats, the renal effects of candesartan
may be mediated through mechanisms that are indepen-
dent of arterial pressure.
CONCLUSION
The results of the present study indicate that the in-
trarenal renin-angiotensin system is not suppressed in DS
hypertensive rats. The renoprotective effects of AT1 re-
ceptor blockade might be, at least partially, due to reduc-
tions in intrarenal Ang II levels and MAPKs activities,
which are not dependent on arterial pressure changes.
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